Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07405164 | Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) | recruiting | Phase 3 | 450 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Sep 23, 2026 | clinicaltrials |
| NCT07504458 | Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia(QUATRO-APL) | recruiting | Phase 3 | 150 | Quetzal TherapeuticsINDUSTRY | 5 | Sep 23, 2026 | clinicaltrials |
| NCT07708753 | A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | recruiting | Phase 3 | 460 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07836530 | Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 492 | BeOne MedicinesINDUSTRY | 0 | Sep 23, 2026 | clinicaltrials |
| NCT02491632 | Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer | active not recruiting | Phase 2 / Phase 3 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | active not recruiting | Phase 3 | 298 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03815643 | Avelumab Program Rollover Study | active not recruiting | Phase 3 | 205 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT03839771 | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy(HOVON150AML) | active not recruiting | Phase 3 | 968 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 15 | Sep 22, 2026 | clinicaltrials |
| NCT04810078 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread(CheckMate-67T) | active not recruiting | Phase 3 | 681 | Bristol-Myers SquibbINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT05009836 | Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC(SANOVO) | active not recruiting | Phase 3 | 412 | HutchmedINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06109272 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-2) | active not recruiting | Phase 2 / Phase 3 | 89 | AbbVieINDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT06140836 | A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) | active not recruiting | Phase 3 | 190 | Bristol-Myers SquibbINDUSTRY | 21 | Sep 22, 2026 | clinicaltrials |
| NCT06151574 | Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | active not recruiting | Phase 3 | 428 | Boehringer IngelheimINDUSTRY | 26 | Sep 22, 2026 | clinicaltrials |
| NCT06703476 | A Study of Surgical Techniques During Cystectomy | recruiting | Phase 3 | 530 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT06712316 | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | recruiting | Phase 2 / Phase 3 | 1,580 | BioNTech SEINDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT06780670 | Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy(PSMAcTION) | recruiting | Phase 2 / Phase 3 | 443 | Novartis PharmaceuticalsINDUSTRY | 13 | Sep 22, 2026 | clinicaltrials |
| NCT06855277 | Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC(AcTFirst) | recruiting | Phase 3 | 940 | Novartis PharmaceuticalsINDUSTRY | 12 | Sep 22, 2026 | clinicaltrials |
| NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | recruiting | Phase 3 | 630 | Mirati Therapeutics Inc.INDUSTRY | 35 | Sep 22, 2026 | clinicaltrials |
| NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | recruiting | Phase 2 / Phase 3 | 500 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 22, 2026 | clinicaltrials |
| NCT07213674 | A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 750 | AmgenINDUSTRY | 18 | Sep 22, 2026 | clinicaltrials |
| NCT07218380 | A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract(FORAGER-2) | recruiting | Phase 3 | 450 | Eli Lilly and CompanyINDUSTRY | 19 | Sep 22, 2026 | clinicaltrials |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | recruiting | Phase 3 | 614 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 22, 2026 | clinicaltrials |
| NCT07522073 | A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma(DAWN-303) | recruiting | Phase 3 | 588 | Incyte CorporationINDUSTRY | 22 | Sep 22, 2026 | clinicaltrials |
| NCT07816380 | A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 3 | 216 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 0 | Sep 22, 2026 | clinicaltrials |
| NCT07833839 | ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma | not yet recruiting | Phase 3 | 440 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Sep 22, 2026 | clinicaltrials |
| NCT02003222 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 488 | National Cancer Institute (NCI)NIH | 4 | Sep 21, 2026 | clinicaltrials |
| NCT04096066 | A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant(KRdvsRd) | active not recruiting | Phase 3 | 84 | Fondazione EMN Italy OnlusOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04534205 | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1(AHEAD-MERIT) | active not recruiting | Phase 2 / Phase 3 | 358 | BioNTech SEINDUSTRY | 21 | Sep 21, 2026 | clinicaltrials |
| NCT05008848 | Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | recruiting | Phase 3 | 600 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05377047 | Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer(TAORMINA) | recruiting | Phase 3 | 345 | Vastra Gotaland RegionOTHER_GOV | 6 | Sep 21, 2026 | clinicaltrials |
| NCT05454280 | Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II) | active not recruiting | Phase 3 | 526 | Fox Chase Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05894239 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer(INAVO122) | recruiting | Phase 3 | 230 | Hoffmann-La RocheINDUSTRY | 29 | Sep 21, 2026 | clinicaltrials |
| NCT06258811 | Neoadjuvant Immunochemotherapy for LAOSCC | recruiting | Phase 3 | 134 | Lai-ping ZhongOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06549595 | A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients | recruiting | Phase 3 | 1,018 | AstraZenecaINDUSTRY | 24 | Sep 21, 2026 | clinicaltrials |
| NCT06732401 | Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 630 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06798363 | Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma | recruiting | Phase 2 / Phase 3 | 32 | West China HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06811038 | iCanQuit Smoking Cessation Among Hispanic Adults | not yet recruiting | Phase 3 | 854 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07132463 | Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study | recruiting | Phase 3 | 196 | Fudan UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07431827 | MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)(KANDLELIT-013) | recruiting | Phase 3 | 400 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Sep 21, 2026 | clinicaltrials |
| NCT07750158 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease(STELLAR-316) | recruiting | Phase 3 | 600 | ExelixisINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07804056 | A Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer | recruiting | Phase 3 | 194 | Hamlet Pharma ABINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829783 | A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)(TroFuse-055) | not yet recruiting | Phase 3 | 400 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07830511 | RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial(RIDDLELN) | not yet recruiting | Phase 3 | 206 | Robert FörsterOTHER | 0 | Sep 21, 2026 | clinicaltrials |
| NCT07831824 | Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])(SPARROW) | recruiting | Phase 2 / Phase 3 | 408 | Lantheus Medical ImagingINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831863 | A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy | not yet recruiting | Phase 3 | 600 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831902 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer(NSMP-ORANGE) | recruiting | Phase 3 | 600 | University College, LondonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials